Brief: Ardelyx Shares Positive Data On Symptom Response During Treatment With Ibsrela (Tenapanor) For IBS-C
23/10/2023 14:29
Oct 23 (Reuters) - Ardelyx Inc ARDX.O :
* ARDELYX SHARES POSITIVE DATA ON SYMPTOM RESPONSE DURING
TREATMENT WITH IBSRELA® (TENAPANOR) FOR IBS-C AND HOSTS IBS-C
PRODUCT THEATER AT ACG 2023
Source text for Eikon: ID:nGNX7NyztP
Further company coverage: ARDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ardelyx
See all newsArdelyx, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectations
Brief: Ardelyx Q2 Product Sales USD 118.129 Million
Ardelyx Q1 product revenue rises 38% on IBSRELA growth
Brief: Ardelyx Q1 Product Sales USD 93.373 Million